Top Greenwich LifeSciences Insider Makes Bold New Bet on the Company’s Future

New insider activity at Greenwich LifeSciences ( (GLSI) ) has taken place on December 19, 2025.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential Greenwich LifeSciences saw insider buying activity as CEO and CFO Snehal Patel acquired 4,100 shares of the company’s stock in a recent transaction. The total value of the purchase amounted to $51,742, signaling a notable show of confidence from the company’s top executive and financial officer in Greenwich LifeSciences’ future prospects. Recent Updates on GLSI stock Over the last 24 hours, trading in Greenwich LifeSciences has centered on a string of clinical and corporate updates rather than any new fundamental shift in guidance. The company reported an approximately 80% reduction in breast cancer recurrence rates in the fully enrolled, 250‑patient open‑label non‑HLA‑A*02 arm of its Phase III FLAMINGO‑01 trial for GLSI‑100, based on comparisons to historical TDM1 data and to recurrence rates before versus after patients complete the primary immunization series. Management emphasized that these data are preliminary, derived without a direct placebo arm, and that final outcomes could differ, but the magnitude of the early efficacy signal and its consistency with prior Phase IIb results are the key drivers behind the current favorable analyst view and associated price target assumptions about GLSI‑100’s potential competitiveness versus existing therapies. Additional support for sentiment comes from steady operational execution—completion of enrollment in the non‑HLA‑A*02 arm, screening of over 1,000 patients across 140 active sites, and a strategy to continue enrolling both genetic subgroups until interim analyses refine optimal trial sizing—along with corporate stability reflected in the re‑election of all directors and retention of the company’s auditor at the recent annual meeting. These developments help underpin expectations for the company’s long‑term oncology pipeline value rather than reflecting any short‑term trading anomaly or macro‑driven move in the stock price. More about Greenwich LifeSciences YTD Price Performance: 5.54% Average Trading Volume: 156,464 Technical Sentiment Signal: Buy Current Market Cap: $148.8M